Duality Advisers LP Sells 8,966 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Duality Advisers LP cut its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 12.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 64,842 shares of the biotechnology company’s stock after selling 8,966 shares during the period. Duality Advisers LP’s holdings in Ironwood Pharmaceuticals were worth $742,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Signaturefd LLC raised its position in Ironwood Pharmaceuticals by 61.4% in the fourth quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 822 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in Ironwood Pharmaceuticals by 10.7% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 15,330 shares of the biotechnology company’s stock valued at $175,000 after purchasing an additional 1,483 shares during the last quarter. Daiwa Securities Group Inc. raised its position in Ironwood Pharmaceuticals by 331.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,473 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,900 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Ironwood Pharmaceuticals by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,997 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,961 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its stake in shares of Ironwood Pharmaceuticals by 5.3% in the third quarter. Teacher Retirement System of Texas now owns 39,641 shares of the biotechnology company’s stock valued at $382,000 after buying an additional 2,002 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. StockNews.com cut Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 6th. Piper Sandler increased their price target on Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Wells Fargo & Company decreased their price target on Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, March 1st. Finally, Craig Hallum assumed coverage on Ironwood Pharmaceuticals in a research note on Wednesday, January 17th. They issued a “buy” rating and a $21.00 price target for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.80.

Insider Buying and Selling

In related news, SVP Andrew Davis sold 9,846 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, February 12th. The stock was sold at an average price of $15.24, for a total transaction of $150,053.04. Following the sale, the senior vice president now directly owns 208,324 shares in the company, valued at $3,174,857.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Ironwood Pharmaceuticals news, SVP Andrew Davis sold 9,846 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $15.24, for a total value of $150,053.04. Following the sale, the senior vice president now directly owns 208,324 shares in the company, valued at $3,174,857.76. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CMO Michael Shetzline sold 38,618 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $15.24, for a total value of $588,538.32. Following the completion of the transaction, the chief marketing officer now owns 340,484 shares of the company’s stock, valued at $5,188,976.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 273,008 shares of company stock worth $4,160,642. 13.10% of the stock is owned by company insiders.

Ironwood Pharmaceuticals Stock Performance

IRWD stock opened at $8.10 on Thursday. The stock’s 50 day moving average is $9.77 and its 200-day moving average is $10.68. Ironwood Pharmaceuticals, Inc. has a twelve month low of $7.53 and a twelve month high of $15.70.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.